Who Is Considered for Mitral Valve Clip Repair When Open-Heart Surgery Is Not Advised

The conversation often starts in an ordinary place. A retired teacher in her late seventies notices she has to sit down halfway through changing the bedsheets. Her cardiologist finds a leaking mitral valve, orders scans, and then says the sentence nobody rehearses for: open-heart surgery is not advised in her case. Her first thought is that the door has closed.

It usually hasn’t. Over the past two decades, a catheter-based procedure that clips the valve’s two leaflets together has become a recognized option, and cardiology guidelines now describe fairly specific groups of transcatheter mitral valve repair candidates. The criteria are not about age or courage. They rest on three questions: how sick is the valve, how risky is surgery, and does the anatomy allow a clip to do useful work.

This explainer walks through those questions honestly, including who is asked to wait, what the trials actually showed, and what the days after the procedure tend to look like.

What is mitral regurgitation, and why does the valve start leaking?

The mitral valve sits between the heart’s two left chambers, the left atrium above and the left ventricle below. It has two leaflets, front and back, tethered by fine cords to muscle in the ventricle wall, a little like a parachute held by its lines. When the ventricle squeezes, the leaflets swing shut and blood goes forward to the body. Mitral regurgitation means they fail to seal, so part of each heartbeat leaks backward into the atrium.

Cardiologists split the problem into two families, and the split matters more than most people realize. In primary (or degenerative) regurgitation, the leaflets or cords themselves are damaged: a leaflet floppy and bulging (prolapse), a snapped cord letting a leaflet flail, scarring from earlier rheumatic fever, or infection. The valve is the disease.

In secondary (or functional) regurgitation, the leaflets are structurally normal. The trouble is the ventricle, usually enlarged and weakened after heart attacks or long-standing heart failure. As the chamber balloons, it drags the leaflets apart so they can no longer meet. Here the leak is a consequence of ventricle disease, which is why medicines that shrink and support the ventricle are tried first (MedlinePlus).

Over time a significant leak overloads the left atrium and ventricle, raises pressure in the lungs, and commonly shows up as breathlessness on exertion, fatigue, and ankle swelling, though the picture varies widely and echocardiography, not symptoms, grades the severity (American Heart Association). Knowing which family you fall into is the first fork in the road toward candidacy for any repair.

How does mitral valve clip repair actually work?

The idea is older than the device. Surgeons discovered years ago that stitching the middle of the two leaflets together turns one large, poorly sealing opening into two smaller ones that close more completely. Transcatheter edge-to-edge repair, the formal name for clip repair, borrows that concept and delivers it through a vein rather than through the chest.

Under general anesthesia, the team threads a catheter, a thin flexible tube, from a vein at the top of the thigh up to the right atrium. A small controlled puncture through the thin wall between the two upper chambers lets the catheter cross into the left atrium, directly above the mitral valve. Guidance comes from two live pictures at once: X-ray fluoroscopy and transesophageal echocardiography, an ultrasound probe placed in the food pipe that gives a close-up view of the valve from behind the heart.

The clip is advanced through the valve into the ventricle with its arms open, then drawn back so the arms catch the free edges of both leaflets at the exact spot where the leak is worst. Imagine pinching a billowing bedsheet between two fingers to stop it flapping. The device closes, the echo team measures how much leak remains and how freely blood still flows forward, and the clip is released only when both look acceptable. Sometimes a second device is added beside the first.

The heart never stops and no incision is made in the chest. The catheter is withdrawn, pressure is held on the vein, and the tiny hole in the atrial wall generally closes on its own over the following weeks (Mayo Clinic). The leaflets themselves are not replaced; they are reshaped where they meet.

Why open-heart surgery is sometimes not advised

Here is an opinion worth stating plainly: surgery remains the reference treatment for most severe primary regurgitation, and clip repair exists because some hearts sit inside bodies that cannot safely tolerate an operation. The 2020 ACC/AHA valvular heart disease guideline gives surgical repair its strongest recommendation for symptomatic severe primary regurgitation, and favors repair over replacement when the anatomy permits (ACC/AHA guideline, PubMed).

Open surgery, though, means opening the breastbone or the side of the chest, placing the patient on a heart-lung machine, stopping the heart, and asking the body to recover from all three. Several factors push the calculated risk into the range where surgeons pause:

• Frailty, meaning reduced physiological reserve, often measured by walking speed, grip strength, and independence in daily tasks rather than by birthday.
• Previous heart surgery, which leaves scar tissue that makes re-entry hazardous.
• Severe lung disease, advanced kidney disease, or liver disease that limit recovery from bypass.
• Prior radiation to the chest, or a heavily calcified aorta that cannot be safely clamped.
• A markedly weakened ventricle that may not restart well after the heart is stopped.

Cardiac surgeons use validated risk calculators that combine these variables into an estimated chance of dying or suffering a major complication. When the estimate is high, or when frailty and organ damage make any number unreliable, the team may label the risk “high” or “prohibitive.” Those words are not a verdict on a person’s worth or life expectancy. They are a statement that the cost of the operation is likely to outweigh its gain, and that a different route deserves consideration.

Who are the usual transcatheter mitral valve repair candidates? Primary regurgitation first

For primary regurgitation, where the leaflets themselves are faulty, the guideline pathway is fairly crisp. Transcatheter edge-to-edge repair carries a Class 2a recommendation, meaning it is considered reasonable on moderate-quality evidence, for people who meet four conditions at once (ACC/AHA guideline, PubMed):

• Severe regurgitation confirmed on echocardiography, not moderate or borderline.
• Symptoms attributable to the leak, typically breathlessness or reduced exercise tolerance.
• Surgical risk judged high or prohibitive by a heart team, for the reasons described above.
• Valve anatomy that suits the device, together with an expected life expectancy beyond one year, so the benefit has time to matter.

That last bullet does most of the quiet work. “Suitable anatomy” means the leak arises from a segment of leaflet the clip can reach and hold, that there is enough leaflet tissue to grasp without tearing, that the grasp zone is not heavily calcified, and that the valve opening is wide enough beforehand that narrowing it into two channels will not create mitral stenosis, the opposite problem in which blood struggles to pass forward. A wide flail gap, where a torn leaflet segment floats far from its partner, can also defeat the device.

People without symptoms occupy a different lane. For them, surgery rather than clipping is recommended when the ventricle shows early strain, such as an ejection fraction, the percentage of blood pumped out with each beat, of 60 percent or less, or a left ventricular end-systolic dimension of 40 millimeters or more, provided repair is likely to succeed (ACC/AHA guideline). Clip repair is not typically offered to asymptomatic patients outside trials.

Secondary mitral regurgitation: when the ventricle, not the valve, is the problem

Secondary regurgitation is the more crowded and more contested territory, because the leak is a symptom of a failing ventricle. The first treatment is never a clip. It is heart failure therapy taken to the highest tolerated intensity, drawn from the classes with proven benefit: beta-blockers, renin-angiotensin system inhibitors or the newer neprilysin combination, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, along with a pacing device that resynchronizes the ventricles when conduction is delayed. Doses and combinations are entirely the prescribing team’s call, and this optimization phase can take months, because each medicine is introduced and adjusted in turn.

Only when severe regurgitation and symptoms persist after that effort does the guideline open the door. Transcatheter edge-to-edge repair earns a Class 2a recommendation for secondary regurgitation when all of the following apply (ACC/AHA guideline, PubMed):

• Persistent symptoms in New York Heart Association class II to IV despite optimized medical therapy.
• Left ventricular ejection fraction between 20 and 50 percent.
• Left ventricular end-systolic dimension of 70 millimeters or less.
• Pulmonary artery systolic pressure of 70 millimeters of mercury or less.

Why the numbers? They describe a ventricle that is weakened but not beyond rescue, and lungs not yet locked into fixed high pressure. They were drawn from the population enrolled in the large US randomized trial that found benefit, and they encode a concept cardiologists call “disproportionate” regurgitation: a leak that is large relative to the ventricle’s size, and therefore likely to be contributing to symptoms rather than merely reflecting a heart that is failing for other reasons (COAPT trial, PubMed). A hugely dilated ventricle with a modest leak sits outside those bounds, and clipping it is unlikely to help.

Who is not a candidate for mitral valve repair with a clip, and who is asked to wait

Being turned down for a clip is common, and the reasons fall into two very different bins: “not the right treatment” and “not yet.” Confusing the two causes unnecessary grief.

People are generally not candidates when the anatomy will not cooperate: a valve opening already too small, so that clipping would create stenosis; heavy calcification exactly where the device must grip; leaflets too short or too thickened by rheumatic disease to hold; a very wide flail gap; or a deep cleft splitting a leaflet. Active infective endocarditis, an infection growing on the valve, rules the procedure out until treated. So does a leak that is only mild or moderate, because the risks of any intervention outweigh a small benefit. When another illness, such as an advanced cancer or end-stage lung disease, is expected to dominate the coming year, most heart teams conclude the procedure cannot deliver enough to justify itself.

Perhaps counterintuitively, a person fit enough for surgery is also usually not a clip candidate. Surgical repair reduces the leak more completely and has the longer durability record, so guidelines steer lower-risk patients toward the operating room (ACC/AHA guideline).

The “not yet” group is larger than people expect. Someone with secondary regurgitation whose heart failure medicines have not been fully optimized is asked to complete that work first. A recent heart attack, an uncontrolled fluid overload, an acute infection, or unstable kidney function all tend to postpone rather than cancel. And someone with severe primary regurgitation but no symptoms and a ventricle still coping is often placed on surveillance echocardiography, typically every six to twelve months, with the decision revisited if things change (Mayo Clinic). “Wait” here means watch, not ignore.

How the heart team decides on transcatheter mitral valve repair candidates

No single doctor makes this call. Guidelines require a multidisciplinary heart team, meaning a group that includes a cardiac surgeon, an interventional cardiologist who performs catheter procedures, an imaging cardiologist, a heart failure specialist, an anesthesiologist, and often a geriatrician or nurse coordinator (ACC/AHA guideline). The point is friction: a surgeon who thinks the operation is feasible and an interventionalist who thinks the anatomy is unsuitable should argue it out with the images on the screen.

The evaluation itself is a sequence rather than a single visit. A standard transthoracic echocardiogram, the chest-surface ultrasound, grades the leak and measures the ventricle. Transesophageal echocardiography then maps the leaflets in three dimensions, locating the exact jet and measuring gap, leaflet length, calcification, and the valve area that would remain after clipping. A CT scan may check the veins for access and the atrial wall for the puncture. Cardiac catheterization measures lung pressures and checks the coronary arteries, since a blocked artery might be the better target. Blood tests look at kidney function, because contrast dye and the procedure stress the kidneys.

Then comes the part that imaging cannot do. Frailty is assessed with simple tools such as a timed walk, grip strength, or questions about daily independence. Cognition and mood are considered, because recovery needs participation. Above all, the team asks what the person wants from the next years. Someone who mainly wants to stop being admitted to hospital for fluid on the lungs has a different calculus from someone hoping to hike again.

The most useful thing a patient can do in this process is answer that question honestly, and ask the team to say out loud what the procedure could realistically change and what it could not.

Mitral clip vs open heart surgery: how the two paths compare

Neither option is universally better; each is better for a particular person. The comparison below summarizes how they typically differ, drawing on guideline descriptions and general patient information rather than any single center’s experience (Mayo Clinic; ACC/AHA guideline).

Feature	Transcatheter edge-to-edge (clip) repair	Open-heart mitral surgery
Access	Catheter through a thigh vein; no chest incision	Breastbone incision or smaller side-of-chest incision
Heart-lung machine	Not used; heart keeps beating	Used; heart is stopped during repair
What is done to the valve	Leaflets clipped together at the leak; annulus untouched	Leaflet resection or reshaping, cord repair, and a support ring; or full replacement
Completeness of leak reduction	Usually reduced to mild or moderate; less often eliminated	Usually reduced to trace or none when repair succeeds
Long-term durability data	Several years of follow-up in trials and registries	Decades of follow-up
Typical hospital stay	Generally shorter, often a day or two	Generally longer, measured in days to a week or more
Guideline position	Class 2a for selected high-risk primary and secondary regurgitation	Class 1 for symptomatic severe primary regurgitation at acceptable risk
Usually chosen for	High or prohibitive surgical risk with suitable anatomy	Patients fit enough for surgery, especially younger ones

Two rows deserve emphasis. Surgery treats the annulus, the valve’s supporting ring, which often enlarges alongside the leak; a clip does not, and that is one reason surgical repairs tend to seal more completely. Conversely, the absence of a heart-lung machine is precisely why clipping is tolerable for people whose lungs, kidneys, or reserve could not withstand bypass. Read the table as a description of trade-offs, and then let the heart team explain which trade-offs apply to your own scan.

Transcatheter mitral valve repair recovery time: the first days and weeks

Because nothing is cut in the chest, the recovery arc is shorter than after surgery, though “shorter” is not “instant,” and general anesthesia alone leaves most older adults tired for several days.

The first hours are spent lying flat while the puncture in the thigh vein seals, with nurses checking the site and pulses in the leg. Most people are awake and eating that evening. A follow-up echocardiogram the next morning confirms the clip is stable and measures the residual leak and forward flow. General patient guidance describes hospital stays after transcatheter valve procedures as typically shorter than after open surgery, commonly a night or two, though frailty or heart failure can extend that (Mayo Clinic).

The first week at home is mostly about the groin. Teams usually ask for gentle walking from day one, no heavy lifting or straining for roughly a week or as they specify, and watching the site for swelling or bleeding. Bruising is expected; a growing lump is not.

Medicines change in two ways. Antiplatelet or anticoagulant therapy, drugs that reduce clot formation on the new device while tissue grows over it, is prescribed for a period the treating team defines, and anyone already taking a blood thinner for atrial fibrillation will have the plan adjusted rather than duplicated. Heart failure medicines continue and may later be fine-tuned as the ventricle adjusts to less backward flow.

Symptom change is gradual. Some people notice easier breathing within days as pressure in the lungs falls; for others, particularly with secondary regurgitation, the gain unfolds over weeks as fluid balance settles. Guidelines call for a follow-up echocardiogram around thirty days and again at a year, then as needed (ACC/AHA guideline). Cardiac rehabilitation, where offered, is a sensible way to rebuild stamina safely.

What the evidence shows, and where it stays uncertain

Honest answer first: the evidence for clip repair is real but narrower than the enthusiasm sometimes surrounding it.

For primary regurgitation, the early randomized comparison against surgery found that surgery reduced the leak more completely and required fewer repeat procedures, while the clip caused fewer major early complications. That trade-off, cited in the ACC/AHA guideline, is exactly why the recommendation is limited to people who cannot safely have the operation rather than offered to everyone (ACC/AHA guideline, PubMed). Much of the primary-regurgitation experience since comes from registries, which show how the device performs in practice but cannot prove it beats an alternative.

For secondary regurgitation, two randomized trials published within months of each other reached different conclusions. The large US trial enrolled patients with severe leaks and moderately damaged ventricles on carefully maximized medicines, and reported fewer heart failure hospitalizations and lower mortality over two years with clip plus medical therapy than with medical therapy alone (COAPT trial, PubMed). A French trial with less severe leaks, larger ventricles, and less standardized medication found no difference. The ventricle-size and pressure limits now written into guidelines are an attempt to select the patients who resemble the trial that showed benefit. Whether those limits are exactly right remains an active research question.

Durability beyond several years is documented but thinner than for surgery, which has decades of follow-up. Transcatheter mitral valve replacement, in which an entire new valve is delivered by catheter, is a separate technology still largely confined to clinical trials and highly selected cases, so no reliable long-term success figures exist for it. Anyone quoting a single tidy percentage for “the mitral procedure” is blurring several distinct things.

Mitral valve clip risks and the alternatives, in plain language

Every procedure that enters the heart carries risk, and clip repair is no exception, even though it avoids the chest. The complications the heart team will discuss include:

• Bleeding or vessel injury at the thigh puncture, the most frequent problem and usually manageable.
• The device attaching to only one leaflet, or detaching later, which may leave the leak unchanged and can require a repeat procedure or surgery.
• Residual regurgitation that is less reduced than hoped.
• Creating mitral stenosis, meaning the clipped valve now restricts forward flow, which is why pre-procedure valve area is measured so carefully.
• A persistent hole in the wall between the atria, called an iatrogenic atrial septal defect, which usually closes but occasionally needs attention.
• Fluid around the heart from a perforation (pericardial effusion), stroke from a dislodged clot, heart rhythm disturbances, kidney strain from contrast dye, and the general risks of anesthesia.
• Rarely, urgent conversion to open surgery.

Guidelines and patient information sites describe these in neutral terms rather than reassuring ones, and the right frame is comparative: what is the risk of the procedure set against the risk of living with the untreated leak, and against the risk of surgery in this particular body (Mayo Clinic)?

The alternatives are also part of a fair conversation. Optimized medical therapy alone, with diuretics to manage fluid and disease-modifying heart failure drugs, is a legitimate choice, especially when symptoms are mild. Surgical repair through a smaller side incision may be feasible for some judged borderline. Cardiac resynchronization pacing can shrink secondary regurgitation in the right candidates. Enrollment in a trial of transcatheter replacement is an option for a few. And for people whose overall health is declining, supportive and palliative care focused on comfort and symptom control is a valid, respected path that heart teams should raise without being asked.

What people often get wrong about mitral valve clip repair

Some misunderstandings surface in nearly every clinic conversation, and correcting them early saves disappointment.

“The clip is the easier version, so everyone should get it.” Guidelines say the opposite for people fit enough to have surgery. Surgical repair reduces the leak more completely and has the longer track record; the clip earns its place precisely when the operation is too dangerous (ACC/AHA guideline).

“They’re replacing my valve.” They are not. The clip reshapes the existing leaflets where they meet. Catheter-based replacement of the whole mitral valve is a different, still largely experimental technology.

“Afterward the leak is gone.” Usually it is reduced, often substantially, from severe to mild or moderate. Complete elimination happens but is not the expected result, and follow-up echocardiograms exist to track what remains.

“I’m too old.” Age is one input into surgical risk, never a stand-alone rule for or against the clip. Frailty, organ function, anatomy, and personal goals carry more weight than the number on a birth certificate.

“Once it’s clipped I can stop my heart pills.” In secondary regurgitation especially, the clip is added on top of heart failure medicines, not instead of them. Any change to medication is the prescribing team’s decision.

“It fixes heart failure.” It treats one contributor to symptoms. The underlying weakened ventricle remains, which is why the ventricle-size limits exist.

“If it fails I can never have surgery.” A clip can make later surgical repair harder, and replacement is more likely than repair if surgery is eventually needed. That is a genuine consideration to raise, not a closed door.

“Not advised for surgery means there is nothing to do.” That belief keeps people from asking the next question, and the next question is the whole point of this article.

Questions to ask your care team

A heart team meeting can feel like being talked about rather than talked with. Bringing a short list, and a companion to take notes, changes the dynamic. These questions map onto the decisions the team is actually weighing, and none of them should be unwelcome.

• Is my regurgitation primary or secondary, and how severe is it on my most recent echocardiogram?
• Why is open surgery not advised for me specifically, and what risk score or factors drove that judgment?
• If my regurgitation is secondary, are my heart failure medicines fully optimized, and how long has that process run?
• On the transesophageal echo, which features make my valve suitable or unsuitable for a clip? Is there enough valve area to avoid stenosis afterward?
• What is a realistic expectation for how much the leak will be reduced, and what change in my daily life might follow?
• Which complications are you most concerned about in my case, and what would happen if the clip did not hold?
• What blood-thinning medicines will I need afterward, for roughly how long, and how does that interact with what I already take?
• What is the follow-up schedule, and who do I call if something feels wrong?
• If I choose to continue medical therapy alone, what would you expect over the next year?
• Would surgery or a replacement still be possible later if this does not work?

Two questions sit above the rest. Ask the team to describe the alternative they would recommend if the clip were not available; the answer reveals how strongly they believe in the procedure for you. And ask what outcome you personally care about most, then say it out loud. Fewer hospital admissions, climbing stairs to a grandchild’s bedroom, or simply avoiding a long recovery are all legitimate goals, and the right plan depends on which one is yours.

When to call your doctor

Most recoveries are uneventful, but a few warning signs need prompt attention, both while waiting for a decision and in the weeks after a procedure. Living with severe regurgitation is itself a reason to stay alert to change.

Call emergency services immediately, rather than waiting for a clinic call-back, for: chest pain or pressure; sudden or rapidly worsening breathlessness, especially if you cannot lie flat or wake gasping; fainting or near-fainting; or any stroke sign, such as a drooping face, weakness in an arm or leg, slurred speech, or sudden confusion. Heavy bleeding from the groin that does not stop with firm pressure also warrants an emergency call.

Contact your cardiology team the same day for: a growing, painful, or hard lump at the puncture site; a leg that becomes cold, pale, numb, or swollen; fever or chills, which can signal infection at the site or on the device; a racing or irregular heartbeat that is new or persistent; rapid weight gain over a few days, or new ankle and abdominal swelling, which often mean fluid is accumulating; dizziness when standing; or breathlessness that is clearly worse than before the procedure (NHS).

Fever deserves a special word. Anyone with a heart valve problem or an implanted device is more vulnerable to endocarditis, an infection settling on the valve, and an unexplained fever lasting more than a day or two should be reported rather than waited out. Tell dentists and other clinicians about the clip before any procedure so they can advise on prevention.

None of these signs means something has certainly gone wrong. They mean the people who know your heart should look, and the decision about what to do next belongs to them.

Frequently asked questions

Who qualifies for mitral clip repair when surgery is off the table?

People with severe, symptomatic mitral regurgitation whose surgical risk a heart team rates high or prohibitive, whose leaflets can be safely grasped without creating a narrowed valve, and whose overall health gives them a reasonable expectation of benefiting for more than a year. In secondary regurgitation, symptoms must persist despite fully optimized heart failure medicines and the ventricle must fall within guideline size and pressure limits. The final decision rests with the treating team.

Who is not a candidate for mitral valve replacement or clip repair?

For clip repair, people with only mild or moderate leaks, unsuitable anatomy such as a small valve area or heavy calcification at the grasp point, active valve infection, or another illness expected to dominate the coming year are generally not candidates. Someone fit for surgery is usually directed to surgery instead. Catheter-based mitral replacement remains largely investigational, so eligibility is confined to trials and highly selected cases decided by a heart team.

Is mitral valve repair a big deal?

Yes, in the sense that any procedure entering the heart under general anesthesia carries real risks and requires careful selection and follow-up. It is less of an ordeal than open surgery because there is no chest incision and the heart is not stopped, and hospital stays are typically shorter. Treating it as minor, though, leads people to skip the questions about residual leak, medicines, and follow-up that matter most.

How long does it take to recover from transcatheter mitral valve repair?

General patient guidance describes hospital stays after transcatheter valve procedures as typically shorter than after open surgery, often a night or two, with a follow-up echocardiogram before discharge. The thigh puncture site needs about a week of care with no heavy lifting, and tiredness from anesthesia can last several days. Symptom improvement may unfold over weeks, with guideline follow-up echocardiograms around thirty days and one year. Your team sets your own timeline.

What is the success rate of transcatheter mitral valve replacement?

There is no reliable single figure, because catheter-based replacement of the whole mitral valve is a different technology from clip repair and is still largely confined to clinical trials and highly selected patients. For clip repair, guidelines cite randomized evidence that in carefully selected secondary regurgitation it reduced heart failure hospitalizations compared with medicines alone, while a second trial found no benefit. Ask your team for outcomes specific to your situation rather than a headline percentage.

Does clip repair stop the mitral leak completely?

Usually it reduces the leak substantially, most often from severe to mild or moderate, rather than eliminating it. The clip joins the leaflets where the jet is worst but does not treat the enlarged supporting ring that surgery would address. Follow-up echocardiograms track what remains. A residual mild leak is generally considered an acceptable result, and your team will explain what degree of reduction they expect from your anatomy.

Am I too old for a mitral valve clip?

Age by itself does not decide candidacy. Heart teams weigh frailty, kidney and lung function, cognition, valve anatomy, and personal goals far more heavily than the birth date, and many people considered for clip repair are in their eighties because surgery is judged too risky for them. Conversely, a very frail person of any age may be advised that neither procedure would help. The assessment is individual.

Will I still need heart medicines after mitral clip repair?

Almost always, yes. Clot-preventing antiplatelet or anticoagulant medicines are prescribed for a period after the device is placed, and in secondary regurgitation the clip is added on top of heart failure therapy rather than replacing it. Some medicines may be adjusted later as the ventricle adapts. Every change belongs to the prescribing clinician; never stop or alter a heart medicine on your own after the procedure.

Can I still have open-heart surgery if the clip does not work?

Often yes, but it is more complicated. A clip can damage or fuse the leaflet tissue a surgeon would otherwise repair, so if surgery becomes necessary later, valve replacement is more likely than repair. Because the clip is offered mainly to people already judged too high-risk for surgery, this scenario is uncommon, but it is a legitimate question to raise with the heart team before deciding.

What tests decide whether I am a candidate for mitral clip repair?

A standard echocardiogram grades the leak and ventricle, then transesophageal echocardiography maps the leaflets closely to measure gap, length, calcification, and the valve area that would remain after clipping. A CT scan may check access veins, cardiac catheterization measures lung pressures and coronary arteries, and blood tests assess kidney function. Frailty assessments such as a timed walk complete the picture before the heart team discusses the case together.

References

• NHS: Mitral valve problems
• MedlinePlus: Mitral regurgitation

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.